BXTAccelyon (BXTA) is a provider of prostate biopsy and brachytherapy products designed for prostate cancer therapy to diagnose and treat prostate cancer. The company offers a product portfolio that includes brachytherapy seeds, brachytherapy accessories, and prostate biopsy products.In 2017, Elysian Capital, a UK-based private equity firm, acquired BXTAccelyon from Pharmaserve (North West) Limited. This acquisition was made through Elysian Capital II LP, a £250 million fund closed in July 2015. The partnership with Elysian Capital aimed to support BXTAccelyon's growth strategy and expand its presence in the global prostate cancer treatment market.Under Elysian Capital's ownership, BXTAccelyon has continued to invest in its product offerings and global expansion. In 2020, the company became the global distribution partner for a new online prostate MRI self-learning tool designed to enhance prostate cancer diagnosis. This partnership demonstrates BXTAccelyon's commitment to improving prostate cancer outcomes through innovative solutions.In 2021, BXTAccelyon announced its physical expansion into continental Europe, with the establishment of a new distribution warehouse and office in the Netherlands. This investment was made to minimize lead times for clients and mitigate the risk of supply chain disruption arising from Brexit. The company also appointed Wilco van der Lugt as Commercial Director for Europe to lead its business expansion in the region.